Liver/Biliary
  • What are the Long-term Effects of DAA Therapy on HCV-associated Cryoglobulinemia Vasculitis?

What are the Long-term Effects of DAA Therapy on HCV-associated Cryoglobulinemia Vasculitis?

More than 95% of patients with hepatitis C virus–associated cryoglobulinemia vasculitis (HCV-CryoVas) have a full or partial response of symptoms to treatment with direct-acting antiviral (DAA) agents, researchers report in a long-term follow-up study in the February issue of Clinical Gastroenterology and Hepatology. Fewer than 5% of patients stopped therapy

Read more
  • What Are the Effects of Virologic Response to Treatment on Outcomes of Patients With Chronic HBV Infection and Decompensated Cirrhosis?

What Are the Effects of Virologic Response to Treatment on Outcomes of Patients With Chronic HBV Infection and Decompensated Cirrhosis?

Maintained virologic response to entecavir or lamivudine associates with short- and long-term transplant-free survival of patients with hepatitis B virus (HBV)-related decompensated cirrhosis, researchers report in the December issue of Clinical Gastroenterology and Hepatology. The benefits are maintained for up to 10 years, but patients are still at risk for

Read more
  • Has MELD-Na Improved Outcomes of Patients on the Liver Transplant Waitlist?

Has MELD-Na Improved Outcomes of Patients on the Liver Transplant Waitlist?

Liver allocation based on model for end-stage liver disease-sodium (MELD-Na) score improved waitlist outcomes and provided significant benefit to patients with hyponatremia, researchers report in the November issue of Gastroenterology. However, there are discrepancies in transplantation survival benefit, so current rules for liver allocation might require revision, the authors state. The

Read more
  • Should We Screen for HCC?

Should We Screen for HCC?

Screening patients with cirrhosis for hepatocellular carcinoma (HCC) by abdominal ultrasonography (USS) and/or measurement of serum level of alpha-fetoprotein (AFP) is not associated with reduced mortality from this cancer, reseachers report from a matched case–control study in the October issue of Gastroenterology. Patients with cirrhosis have a high risk (1%–8%

Read more
  • Does Colony Stimulating Factor Increase Survival of Patients with Alcoholic Hepatitis?

Does Colony Stimulating Factor Increase Survival of Patients with Alcoholic Hepatitis?

In a pilot study from the October issue of Clinical Gastroenterology and Hepatology, colony stimulating factor 3 (CSF3, also called GCSF) improved liver function and increased survival times in patients with severe alcohol-associated hepatitis (AH), compared with standard therapy. Addition of N-acetyl cysteine (NAC) to GCSF did not improve patient outcomes. Patients

Read more
  • How Many Cases of Drug-Induced Liver Injury Are Caused by Herbal and Dietary Supplements?

How Many Cases of Drug-Induced Liver Injury Are Caused by Herbal and Dietary Supplements?

Herbal and dietary supplement-induced liver injury is more severe than other types of drug-induced liver injury (DILI), and re-exposure is more likely, researchers report in the September issue of Clinical Gastroenterology and Hepatology. Increasing awareness of the hepatoxic effects of herbal and dietary supplements could help physicians make earlier diagnoses

Read more
  • 500 Posts by the AGA Journals Blog

500 Posts by the AGA Journals Blog

This week the AGA Journals Blog has reached an important milestone — its 500th post! The blog was started in 2010 to help disseminate the important discoveries published in the AGA Journals to a broader audience. Eight years and over 132,000 views later, it has updated its readers on everything from biomarkers for colon

Read more
  • A Genetic Cause for Multiple Adenomas and Diabetes in a Young Patient

A Genetic Cause for Multiple Adenomas and Diabetes in a Young Patient

Researchers report a case of a patient with multiple adenomas and a family history of young-onset diabetes and hepatocellular carcinoma. They found these to be caused by a mutation in the HNF1 homeobox A gene (HNF1A), which caused maturity onset diabetes of the young type 3 (MODY3). Tom J. Harryvan et al evaluated a

Read more
  • What are the Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis?

What are the Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis?

Vitamin K antagonists (VKAs) increase risk of minor bleeding in patients with cirrhosis given anticoagulants for portal vein thrombosis (PVT), compared to patients without cirrhosis given VKAs, researchers report in the July issue of Clinical Gastroenterology and Hepatology. However, this risk is offset by the ability of VKA to increase portal

Read more
  • Can Nonlytic T cells be Engineered to Fight HBV Infection?

Can Nonlytic T cells be Engineered to Fight HBV Infection?

Nonlytic T cells with receptors engineered to recognize HBV suppress virus replication in hepatocytes and limit infection of mice by activating APOBEC3, researchers report in the July issue of Gastroenterology. These cells are not hepatotoxic and might be developed for treatment of chronic HBV infection. T cells control chronic viral infections, and virus-specific

Read more